Our study first showed the synergistic effects of a BCL2 inhibitor ABT-263 and SM/z-VAD.fmk LCL161 with the aim of identifying a reinforcing anti-cancer effect that can be utilized as novel targeted agents in YARS-positive breast cancer. Here, YARS1 is linked to breast cancer.